Eduardo Netto1,2, Margarida Ferreira3, Susana Esteves4, Isabel Sargento3, Teresa Alexandre3, Rute Pocinho1, Antonio Mota1,2, Miguel Labareda1, Miguel Rito5, José Cabeçadas5, Miguel Magalhães6, Margarida Roldão1,2. 1. Radiation Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. 2. NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal. 3. Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. 4. Clinical Research Unit, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. 5. Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. 6. Otorhinolaryngology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
Abstract
PURPOSE: Report our matured outcomes of European nasopharyngeal carcinoma (NPC) treatment from a non-endemic region in the IMRT era. METHODS: We reviewed 109 consecutive patients with biopsy proven NPC treated between 2009 and 2013. All received IMRT as per RTOG 0615. Toxicity was scored accordingly to CTCAE 4.03. Platinum-based chemotherapy was delivered following the Intergroup 0099. RESULTS: Median age of 53 years; 97% Caucasian; 74% male; 72% WHO grade III; 43% T1; 14% T2; 18% T3, 25% T4; 17% N0; 17% N1; 39% N2; 27% N3. Compliance to adjuvant chemotherapy was 88%. With a median follow up of 56 months, the 4-year local control was 90.2% (88.6% for T1; 100% for T2; 85% for T3; and 91.7% for T4), the 4-year distant metastases-free survival was 86% and an overall survival rate was 77%. Local control and survival were better in G3 (p < 0.001 and p = 0.032, respectively). Xerostomia was the most frequent late toxicity in 55% (n = 60). Hypothyroidism requiring hormonal reposition occurred in 15.5% (n = 17). From the 36 deaths, 20 were due to distant metastases, 3 grade 5 toxicity, 2 from local progression, 5 non-cancer deaths and unknown cause in the remaining 6. On multivariable analysis, age (p = 0.017), local recurrence and distant metastases were associated with death (p < 0.001, both). CONCLUSION: Our matured data from the IMRT era showed a major improvement from our 3D cohort series reaching excellent local and regional control, even in T4. Local recurrences, despite few, and distant metastases were correlated with the risk of death.
PURPOSE: Report our matured outcomes of European nasopharyngeal carcinoma (NPC) treatment from a non-endemic region in the IMRT era. METHODS: We reviewed 109 consecutive patients with biopsy proven NPC treated between 2009 and 2013. All received IMRT as per RTOG 0615. Toxicity was scored accordingly to CTCAE 4.03. Platinum-based chemotherapy was delivered following the Intergroup 0099. RESULTS: Median age of 53 years; 97% Caucasian; 74% male; 72% WHO grade III; 43% T1; 14% T2; 18% T3, 25% T4; 17% N0; 17% N1; 39% N2; 27% N3. Compliance to adjuvant chemotherapy was 88%. With a median follow up of 56 months, the 4-year local control was 90.2% (88.6% for T1; 100% for T2; 85% for T3; and 91.7% for T4), the 4-year distant metastases-free survival was 86% and an overall survival rate was 77%. Local control and survival were better in G3 (p < 0.001 and p = 0.032, respectively). Xerostomia was the most frequent late toxicity in 55% (n = 60). Hypothyroidism requiring hormonal reposition occurred in 15.5% (n = 17). From the 36 deaths, 20 were due to distant metastases, 3 grade 5 toxicity, 2 from local progression, 5 non-cancer deaths and unknown cause in the remaining 6. On multivariable analysis, age (p = 0.017), local recurrence and distant metastases were associated with death (p < 0.001, both). CONCLUSION: Our matured data from the IMRT era showed a major improvement from our 3D cohort series reaching excellent local and regional control, even in T4. Local recurrences, despite few, and distant metastases were correlated with the risk of death.
Authors: Jin-Gao Li; Praveen Venigalla; Jonathan E Leeman; Quincey LaPlant; Jeremy Setton; Eric Sherman; Jillian Tsai; Sean McBride; Nadeem Riaz; Nancy Lee Journal: Laryngoscope Date: 2016-07-20 Impact factor: 3.325
Authors: Charles Mayo; Mary K Martel; Lawrence B Marks; John Flickinger; Jiho Nam; John Kirkpatrick Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: K H Au; Roger K C Ngan; Alice W Y Ng; Darren M C Poon; W T Ng; K T Yuen; Victor H F Lee; Stewart Y Tung; Anthony T C Chan; Henry C K Sze; Ashley C K Cheng; Anne W M Lee; Dora L W Kwong; Anthony H P Tam Journal: Oral Oncol Date: 2017-12-12 Impact factor: 5.337
Authors: Nancy Y Lee; Qiang Zhang; David G Pfister; John Kim; Adam S Garden; James Mechalakos; Kenneth Hu; Quynh T Le; A Dimitrios Colevas; Bonnie S Glisson; Anthony Tc Chan; K Kian Ang Journal: Lancet Oncol Date: 2011-12-15 Impact factor: 41.316